B
Bull
Bull · 25%TRVI
$7.16
Scenario price
$16.790
-1.093 (-6.51%)At close
Loading chart…
- High
- 18.090
- Open
- 17.880
- VWAP
- 17.17
- Vol
- 1.97M
- Mkt Cap
- 207.08M
- Low
- 16.625
- Amount
- 33.86M
- EV/EBITDA, TTM
- 0.00
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
AI analysis of Trevi Therapeutics Inc (TRVI)
buyTrevi Therapeutics Inc is a good buy right now due to its current price of $16.79, which is significantly below the analyst price target of $36, indicating a potential upside of over 114%. Additionally, the company has a strong cash position of approximately $319 million, ensuring operational stability and the ability to fund clinical trials.
Valuation Metrics
The current forward P/E ratio for Trevi Therapeutics Inc (TRVI) is 0.00, compared to its 5-year average forward P/E of -7.54.
Alphio AI Price Scenarios for TRVI
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding TRVI
Events Timeline
News
9.508-07seekingalphaTrevi Therapeutics Q2 2026 Earnings Call Insights
8.507-28GlobenewswireTrevi Therapeutics to Participate in Upcoming Biotech Conferences
8.507-28NewsfilterTrevi Therapeutics to Participate in Upcoming Biotech Conferences
8.507-17seekingalphaGSK Discontinues Chronic Cough Therapy, Trevi Hits All-Time High
9.506-20NASDAQ.COMMultiple Companies Show Strong Stock Performance
TRVI FAQ — answered by Alphio AI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Trevi Therapeutics Inc is a good buy right now due to its current price of $16.79, which is significantly below the analyst price target of $36, indicating a potential upside of over 114%. Additionally, the company has a strong cash position of approximately $319 million, ensuring operational stability and the ability to fund clinical trials.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.